Ophthalmology Consultations™: Keeping an Eye Out for MGD-Associated Dry Eye in Pre/Post-Op Patients – Improving Surgical Outcomes by Optimizing the Surface

Released On
August 26, 2022

Expires On
August 26, 2023

Media Type
Internet

Completion Time
90 minutes

Specialty
Ophthalmology

Topic(s)
Eye Disorders

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by an educational grant from Bausch + Lomb.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credits
  • Nurses — 1.5 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward ophthalmologists and other healthcare professionals involved in treating patients with MGD-associated DED.

Program Overview

Dry eye disease (DED) is one of the most common ocular diseases encountered by eye care professionals, and meibomian gland dysfunction (MGD) is a frequent cause of DED. Historically, treatments for MGD have focused on alleviating symptoms using artificial tears or warming procedures with compression to melt and expel viscous meibum. Pharmacologic therapies comprise antibiotics and immunomodulators directed at inflammation, but no agents have yet been approved by the United States Food and Drug Administration specifically for MGD. Emerging agents may bring new mechanisms for MGD management.

The Ophthalmology Consultations™ is a video-based program in which two experts discuss the treatment and management of management of MGD-associated DED. In this activity the faculty focus on the current and emerging therapeutic strategies for the management of MGD-associated DED. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of MGD-associated DED and to improve outcomes for their patients with this disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess the importance of optimal MGD-associated dry eye recognition and management in preoperative and postoperative patients
  • Identify the mechanisms of agents under investigation for the treatment of MGD-associated DED
  • Analyze safety and efficacy data of emerging therapies being studied for MGD-associated DED

Faculty

FACULTY_NAME

Elizabeth Yeu, MD

Assistant Professor of Ophthalmology
Eastern Virginia Medical School
Medical Director
Virginia Surgery Center
Cornea, Cataract, Anterior Segment and Refractive Surgery
Norfolk, VA

FACULTY_NAME

Michael Greenwood, MD

Ophthalmologist
Vance Thompson Vision
Fargo, ND


Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Elizabeth Yeu, MD
  • Research Support: Alcon, BioTissue, Ocular Science, Tarsus, TearLab Corporation
  • Consultant: Advanced Vision Group, Allergan, Aurion, Avellino, Bausch + Lomb/Valeant, Beaver-Visitec International, Bio-Tissue, BlephEx, Bruder, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Glaukos, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LENSAR, Melt Pharmaceuticals, Merck, Mynosys, Novartis, Ocular Science, OCuSOFT, Omeros, ScienceBased Health, Sight Sciences, STAAR Surgical, Sun Pharmaceutical Industries, Surface Opthalmics, Thea Pharmaceuticals, Tarsus Pharmaceuticals, TearLab Corporation, Visus Therapeutics, Zeiss Pharmaceuticals
  • Speaker’s Bureau: Alcon
  • Other: Advanced Vision Group, Aurion, Avellino, BlephEx, CorneaGen, Equinox, Expert Opinion, LayerBio, Mati Therapeutics, Melt Pharmaceuticals, Modernizing Medicine, Mynosys, Ocular Science, Orasis Pharmaceuticals, STAAR Surgical, Tarsus Pharmaceuticals, Visus Therapeutics
Michael Greenwood, MD
  • Consultant: Allergan, Avellino, Equinox, Expert Opinion, Imprimis, Ivantis, Nevakar, New World Medical, Ocular Therapeutix, Tarsus, Zeiss
  • Honorarium: Aerie, Alcon, Glaukos, Imprimis, Johnson & Johnson, New World Medical, Sight Sciences, STAAR, Valeant
  • Other: Equity Owner: Equinox

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.